| Title: |
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy |
| Authors: |
Duléry, Rémy; Lamure, Sylvain; Delord, Marc; Di Blasi, Roberta; Chauchet, Adrien; Hueso, Thomas; Rossi, Cédric; Drenou, Bernard; Deau Fischer, Bénédicte; Soussain, Carole; Feugier, Pierre; Noël, Nicolas; Choquet, Sylvain; Bologna, Serge; Joly, Bertrand; Philippe, Laure; Kohn, Milena; Malak, Sandra; Fouquet, Guillemette; Daguindau, Étienne; Taoufik, Yassine; Lacombe, Karine; Cartron, Guillaume; Thiéblemont, Catherine; Besson, Caroline M. |
| Contributors: |
CHU Saint-Antoine AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Institut de Génétique Moléculaire de Montpellier (IGMM); Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS); Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Centre Hospitalier de Versailles André Mignot (CHV); Service d'hématologie-oncologie adultes; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité); Service d'hématologie; Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon); Institut Gustave Roussy (IGR); Département d'hématologie Gustave Roussy; Service d'Hématologie Clinique (CHU de Dijon); Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon); Groupe hospitalier de la région de Mulhouse et Sud-Alsace; Hôpital Cochin AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); CRLCC René Huguenin (CRLCC René Huguenin); Hôpital René Huguenin Saint-Cloud; Institut Curie - Saint Cloud (ICSC)-Institut Curie - Saint Cloud (ICSC)-UNICANCER; Service d'Hématologie CHRU Nancy; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy); Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre; CHU Pitié-Salpêtrière AP-HP; Centre Hospitalier Sud Francilien - Centre Hospitalier d'Evry (CHSF); Centre Hospitalier Annecy-Genevois Saint-Julien-en-Genevois; Immunologie intégrative des tumeurs et immunothérapie des cancers (INTIM (U1186)); Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP); Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU); Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse; AP-HP. Université Paris Saclay-AP-HP. Université Paris Saclay-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Roche; Takeda Pharmaceutical Company, TPC; We thank all the clinicians and patients in the participating centers for their contributions to this multicenter study. We are grateful to the Centre Hospitalier de Versailles, in particular Philippe Rousselot and Laure Morisset for promoting the research and for supporting the editing. We thank France Lymphome Espoir for reviewing the study material, LYSA for discussions on the design of this study, and Sophie Rigaudeau and C?cile Laur?ana for their contribution to the collection of the cases.; Rémy Duléry reports personal fees from Takeda, Novartis, and Biotest and non‐financial support from Gilead outside the submitted work. Roberta Di Blasi reports personal fees from Gilead and Novartis outside the submitted work. Serge Bologna reports personal fees from Janssen and Roche outside the submitted work. Guillaume Cartron reports personal fees from Roche, Celgene, Sanofi, Gilead, Janssen, and Abbvie outside the submitted work. Karine Lacombe reports personal fees and non‐financial support from Gilead, MSD, Abbvie, ViiV Healthcare, and Janssen outside the submitted work. Caroline Besson reports research funding from Roche and non‐financial support from Takeda and Roche outside the submitted work. |
| Source: |
ISSN: 0361-8609. |
| Publisher Information: |
CCSD; Wiley |
| Publication Year: |
2021 |
| Collection: |
Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ |
| Subject Terms: |
vaccination; B-cell depleting immunotherapy; anti-CD20 therapy; lymphoma; Covid-19; MESH: COVID-19 / mortality; MESH: Age Factors; MESH: Aged; 80 and over; MESH: B-Lymphocytes / drug effects; MESH: Combined Modality Therapy; MESH: Lymphoma; Non-Hodgkin / complications; MESH: SARS-CoV-2; MESH: COVID-19 / complications; MESH: Antigens; CD20 / immunology; MESH: Rituximab / administration & dosage; [SDV.CAN]Life Sciences [q-bio]/Cancer; [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology; [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases; [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases; [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy; [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie |
| Description: |
International audience ; Prolonged Covid-19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in-hospital stay (LOS) due to Covid-19 among patients with lymphoma and assess its determinants and outcomes. Adult patients with lymphoma admitted for Covid-19 to 16 French hospitals in March and April, 2020 were included. Length of in-hospital stay was analyzed as a competitor vs death. The study included 111 patients. The median age was 65 years (range, 19–92). Ninety-four patients (85%) had B-cell non-Hodgkin lymphoma. Within the 12 months prior to hospitalization for Covid-19, 79 patients (71%) were treated for their lymphoma. Among them, 63 (57%) received an anti-CD20 therapy. Fourteen patients (12%) had relapsed/refractory disease. The median LOS was 14 days (range, 1–235). After a median follow-up of 191 days (3–260), the 6-month overall survival was 69%. In multivariable analyses, recent administration of anti-CD20 therapy was associated with prolonged LOS (subdistribution hazard ratio 2.26, 95% confidence interval 1.42–3.6, p < 0.001) and higher risk of death (hazard ratio 2.17, 95% confidence interval 1.04–4.52, p = 0.039). An age ≥ 70 years and relapsed/refractory lymphoma were also associated with prolonged LOS and decreased overall survival. In conclusion, an age ≥ 70 years, a relapsed/refractory lymphoma and recent administration of anti-CD20 therapy are risk factors for prolonged LOS and death for lymphoma patients hospitalized for Covid-19. These findings may contribute to guide the management of lymphoma during the pandemic, support evaluating specific therapeutic approaches, and raise questions on the efficacy and timing of vaccination of this particular population. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/33909916; PUBMED: 33909916; PUBMEDCENTRAL: PMC8212109; WOS: 000649477000001 |
| DOI: |
10.1002/ajh.26209 |
| Availability: |
https://hal.science/hal-03401859; https://hal.science/hal-03401859v1/document; https://hal.science/hal-03401859v1/file/Manuscript%20prolonged%20Covid%20lymphoma%20AJH_21042021%20accepte%CC%81.pdf; https://doi.org/10.1002/ajh.26209 |
| Rights: |
https://about.hal.science/hal-authorisation-v1/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.10D05042 |
| Database: |
BASE |